转化生长因子βⅡ型受体作为弥漫性大B细胞淋巴瘤的标志物

Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma.

作者信息

Mao Shudan, Yang Wenqi, Ai Limei, Li Zhe, Jin Jieping

机构信息

Department of Hematology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, 121000, China.

Department of Cardiology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, 121000, China.

出版信息

Tumour Biol. 2015 Dec;36(12):9903-8. doi: 10.1007/s13277-015-3700-z. Epub 2015 Jul 14.

DOI:10.1007/s13277-015-3700-z

PMID:26168957

Abstract

The objective of this study was to investigate the expression and significance of the transforming growth factor β type II receptor (TGFβRII) in diffuse large B cell lymphoma. All patients were enrolled at the First Affiliated Hospital of Liaoning Medical University between 2001 and 2007. The median follow-up period was 53.3 months. Of the 338 patients studied, 131 (38.76 %) had TGFβRII positive expression on immunohistochemistry. The 5 year survival rate was significantly higher in patients with TGFβRII expression than in those without TGFβRII expression (40.3 vs. 31.6 %, P = 0.041). Multivariate analysis identified TGFβRII expression as an independent predictive parameter for survival, in addition to lactate dehydrogenase, clinical stage, and histologic subtype. TGFβRII expression may be considered a new prognostic factor of diffuse large B cell lymphoma.

摘要

本研究的目的是探讨转化生长因子βⅡ型受体（TGFβRII）在弥漫性大B细胞淋巴瘤中的表达及意义。所有患者均于2001年至2007年在辽宁医学院附属第一医院入组。中位随访期为53.3个月。在338例研究患者中，131例（38.76%）免疫组化显示TGFβRII呈阳性表达。TGFβRII表达阳性的患者5年生存率显著高于无TGFβRII表达的患者（40.3%对31.6%，P = 0.041）。多因素分析确定TGFβRII表达是除乳酸脱氢酶、临床分期和组织学亚型之外的生存独立预测参数。TGFβRII表达可被视为弥漫性大B细胞淋巴瘤的一个新的预后因素。